[Synergistic effects of davercin, rifampicin, ethambutol and isonicotinic acid hydrazide on selected standard strains of Mycobacterium in the in-vitro and in-vivo experiments].
Janowiec
M
M
Andrzejczyk
Z
Z
Szwedowicz
I
I
D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004917:Erythromycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004977:Ethambutol / Q000494:pharmacology / Q000627:therapeutic use; D066298:In Vitro Techniques; D007538:Isoniazid / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D009161:Mycobacterium / Q000187:drug effects*; D009164:Mycobacterium Infections / Q000188:drug therapy* / Q000382:microbiology; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use
D000995:Antitubercular Agents; C029784:erythromycin A cyclic 11,12-carbonate; D004917:Erythromycin; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin
Skojarzone działanie davercinu z ryfampicyna, etambutolem i hydrazydem kwasu izonikotynowego na dobrane szczepy wzorcowe z rodzaju Mycobacterium w doświadczeniach in vitro i in vivo.